News | August 18, 2025
European Commission grants approval of Ogsiveo
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Vasograin Plus represents a major advancement in the treatment of migraine
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
cSCC is one of the most common cancers in the U.S. and globally
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
Subscribe To Our Newsletter & Stay Updated
